BACAINN THERAPEUTICS
Bacainn creates cutting-edge medicines that target the innate immune system to combat uncontrolled inflammation.
BACAINN THERAPEUTICS
Social Links:
Industry:
Health Care Health Diagnostics Professional Services Therapeutics Wellness
Founded:
2017-01-01
Address:
Concord, Massachusetts, United States
Country:
United States
Website Url:
http://www.bacainntherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF IPv6 Cloudflare Hosting Person Schema Microsoft Exchange Online Office 365 Mail Gravatar Profiles Microsoft Azure DNS Cloudflare DNS GoDaddy Verification
Similar Organizations
la vista chiropractic & wellness center
la vista chiropractic & wellness center is a healthcare industry.
ProSeries
ProSeries manufactures athletic equipment and cold therapy since wrap products that are custom made to control pain and inflamation.
Spa Utopia
Spa Utopia is a health and wellness center that offers a variety of therapies, treatments, and retail products.
Official Site Inspections
http://www.bacainntherapeutics.com
- Host name: 172.67.217.83
- IP address: 172.67.217.83
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Bacainn Therapeutics"
Bacainn Therapeutics - Crunchbase Company Profile & Funding
Organization. Bacainn Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Bacainn creates cutting-edge medicines that โฆSee details»
Bacainn Therapeutics: Revenue, Worth, Valuation & Competitors โฆ
Bacainn Therapeutics is a Biotech related company founded in 2017 and based in Massachusetts with an estimated revenue of $1.9M, and 12 employees. It has 10 competitors including โฆSee details»
Bacainn Therapeutics 2025 Company Profile: Valuation, โฆ
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240277798-A1: Cyclosporine compositions and methods of use: PendingSee details»
Bacainn Therapeutics - VentureRadar
Similar Companies: Adiso Therapeutics USA Privately Held Adiso is a pharmaceutical company that develops innovative medicines to treat inflammatory diseases. Their therapeutic approach โฆSee details»
Bacainn Therapeutics - Overview, News & Similar companies
Jul 9, 2021 Bacainn Therapeutics contact info: Phone number: (781) 290-9076 Website: www.bacainntherapeutics.com What does Bacainn Therapeutics do? Bacainn Therapeutics is โฆSee details»
Bacainn Therapeutics Overview | SignalHire Company Profile
Organization Website: bacainntherapeutics.com : Social Links: Bacainn Therapeutics industries Biotech: Headquarters Location: Greater ... 1-10 employees: Founded: 2017: Bacainn โฆSee details»
Bacainn Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Jul 5, 2023 Explore Bacainn Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Drug:BT-051.See details»
Bacainn Therapeutics Inc - Drug pipelines, Patents, Clinical
Explore Bacainn Therapeutics Inc with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Immune System Diseases, Technology Platform:Small molecule drug, โฆSee details»
Bacainn Therapeutics, Inc.:Company Profile & Technical Research ...
Bacainn Therapeutics is a company that provides Innate immune system, Inflammation and more. Bacainn Therapeutics is headquartered in United States Massachusetts. Bacainn โฆSee details»
Bacainn Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Bacainn Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Bacainn Therapeutics Reports Positive Data from โฆ
Dec 3, 2020 The organization reported the fruitful consummation of the first-in-human preliminary a. Drug Name: BT-051 Bacainn Therapeutics has announced positive outcomes from the Phase I clinical ...See details»
Bacainn Therapeutics | VentureRadar
Find out more about Bacainn Therapeutics, inflammation, Proprietary Compounds and neutrophils. All; Ranked; Organisation Names; Apps and Links. Homepage (myVR) Funding โฆSee details»
Bacainn Therapeutics: Revenue, Competitors, Alternatives
Bacainn Therapeutics 's estimated revenue per employee is $ 155,000Employee Data. Bacainn Therapeutics has 12 Employees. Bacainn Therapeutics; grew their employee count by -20%. โฆSee details»
Bacainn Therapeutics Announces IND Clearance for BT051 and
Jun 9, 2020 CONCORD, Mass.--(BUSINESS WIRE)-- Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDAโs โฆSee details»
Bacainn Therapeutics Reports Positive Topline Results from Phase โฆ
CONCORD, Mass. โ Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced thesuccessful completion of the โฆSee details»
Bacainn Therapeutics Presents at ECCO โ21 Results ... - Business Wire
Jul 9, 2021 Bacainn Therapeutics Presents at ECCO โ21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe โฆSee details»
Bacainn Therapeutics - VentureRadar
Bacainn approaches inflammation differently in gastrointestinal and respiratory diseases. In exploring novel approaches for ulcerative colitis,... ... Find out more ...See details»
Bacainn Therapeutics Reports Positive Topline Results from Phase โฆ
Dec 2, 2020 Bacainn Therapeutics was founded based on the extensive insights into neutrophil biology generated by Dr. Beth McCormickโs laboratory at the University of Massachusetts โฆSee details»
Bacainn Therapeutics reports positive data from ulcerative colitis trial
Dec 3, 2020 Bacainn Therapeutics has reported positive results from the Phase I clinical trial of gut-restricted drug, BT051, for treating inflammatory diseases such as ulcerative colitis. The โฆSee details»
Bacainn Therapeutics Presents at ECCO โ21 Results from
Jul 9, 2021 Bacainn Therapeutics, Inc. today presented results at the European Crohnโs and Colitis Organisationโs 2021 Virtual Congress from a Phase 1 study that showed its lead asset โฆSee details»